

Article

# Pretargeted Imaging with Gallium-68 – Improving the Binding Capability by Increasing the Number of Tetrazine Motifs

Dominik Summer<sup>1</sup>, Sonja Mayr<sup>1</sup>, Milos Petrik<sup>2</sup>, Christine Rangger<sup>1</sup>, Katia Schoeler<sup>3</sup>, Lisa Vieider<sup>4</sup>, Barbara Matuszczak<sup>4</sup> and Clemens Decristoforo<sup>1,\*</sup>

<sup>1</sup> Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria; [dominik.summer@i-med.ac.at](mailto:dominik.summer@i-med.ac.at); [sonja.mayr@student.uibk.ac.at](mailto:sonja.mayr@student.uibk.ac.at); [christine.rangger@i-med.ac.at](mailto:christine.rangger@i-med.ac.at); [clemens.decristoforo@i-med.ac.at](mailto:clemens.decristoforo@i-med.ac.at);


<sup>2</sup> Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic; [milos.petrik@upol.cz](mailto:milos.petrik@upol.cz)

<sup>3</sup> Biocenter - Division of Developmental Immunology, Medical University of Innsbruck, Innrain 80/82, A-6020 Innsbruck, Austria; [katia.schoeler@i-med.ac.at](mailto:katia.schoeler@i-med.ac.at)

<sup>4</sup> Institute of Pharmacy, Pharmaceutical Chemistry, University of Innsbruck, Center for Chemistry and Biomedicine (CCB), Innrain 80/82, A-6020 Innsbruck, Austria; [lisa.vieider@student.uibk.ac.at](mailto:lisa.vieider@student.uibk.ac.at); [barbara.matuszczak@uibk.ac.at](mailto:barbara.matuszczak@uibk.ac.at)

\* Correspondence: [clemens.decristoforo@i-med.ac.at](mailto:clemens.decristoforo@i-med.ac.at); Tel.: +4351250480951

**Abstract:** Among extensive studies on click chemistry the inverse electron-demand Diels-Alder reaction between 1,2,4,5-tetrazine (Tz) and trans-cyclooct-2-en (TCO) has gained increasing attraction due to its exceptionally fast reaction kinetics and high selectivity for *in vivo* pretargeting applications including PET imaging. The facile two-step approach utilizing TCO-modified antibodies as targeting structures has not made it into clinic though as the increase in blood volume from mice to human seems to be the major limitation. This study aimed to show if the design of multimeric Tz-ligands by chelator scaffolding can improve the binding capacity and may lead to enhanced PET imaging with gallium-68. For this purpose we utilized the macrocyclic siderophore Fusarinine C (FSC) which allows to conjugate up to three Tz-residues due to three primary amines available for site specific modification. The resulting mono- di- and trimeric conjugates were radiolabelled with gallium-68 and characterized *in vitro* (logD, protein binding, stability, binding towards TCO modified rituximab (RTX)) and *in vivo* (biodistribution- and imaging studies in normal BALB/c mice using a simplified RTX-TCO tumour surrogate). The <sup>68</sup>Ga-labelled FSC-based Tz-ligands showed suitable hydrophilicity, high stability, high targeting specificity and the binding capacity to RTX-TCO was increased by the grade of multimerization. Corresponding *in vivo* studies showed a multimerization typical profile but generally suitable pharmacokinetics with low accumulation in non-targeted tissue. Imaging studies in RTX-TCO tumour surrogate bearing BALB/c mice confirmed this trend and revealed improved targeting by multimerization as increased accumulation in RTX-TCO positive tissue was observed.



## Graphical Abstract

**Keywords:** pretargeting, Fusarinine C, rituximab, click chemistry, multimerization, PET, gallium-68

---

### 1. Introduction


Immunoglobulins, in particular monoclonal antibodies (mAbs) are highly attractive targeting structures due to their extraordinary specificity and selectivity and are well established for therapeutic applications, particularly in the field of oncology [1,2]. With favorable targeting abilities and an ever increasing clinical importance, mAbs have regained interest also as imaging agents, in particular for positron emission tomography (PET) applications [3-5]. In principle mAbs can be directly radiolabelled either by direct incorporation of radiohalogens or by attaching a chelator to the protein in case of radiometals. However, prolonged circulation time and slow distribution within the organism restricts its use to long-lived radionuclides e.g. zirconium-89 (3.26 d) and iodine-124 (4.18 d). This multiday circulation paired with slow radioactive decay provides unfavorable radiation to healthy tissue and adds significantly to the overall radiation burden of patients.

To overcome this, various pretargeting methodologies have been reported and reviewed recently [6-8], enabling a facile two-step approach. Thereby the modified antibody is administered, allowed to accumulate at the target site and be eliminated from the bloodstream followed by injection of the radioactive payload to form the radioimmunoconjugate *in vivo*. This provides certain advantages as it facilitates the use of short-lived radioisotopes for PET applications e.g. gallium-68 (1.13 h), fluorine-18 (1.83 h) and copper-64 (12.7 h) and reduces the radiation dose to healthy tissue significantly as the radioligand either finds its binding partner to form stable conjugates or is rapidly eliminated due to its small size. Furthermore, it allows to apply radiolabelling at high temperatures using high concentrations of organic solvents if necessary – harsh conditions, where the structural integrity of antibodies would be severely in danger when direct labelling was performed.

Among these pretargeting strategies the inverse electron-demand Diels-Alder reaction (IEDDA) between 1,2,4,5-tetrazines (Tz) and trans-cyclooct-2-enes (TCO) has gained enormous attention mainly due to the exceptionally fast reaction kinetics and high selectivity between the reaction partners even in complex biological systems as encountered *in vivo* [9,10]. Various preclinical studies demonstrated the feasibility of this approach for molecular imaging using PET-radioisotopes with promising results [11-14]. However, the translation from mice to human remains unsuccessful due to increasing blood volume, which may lead to insufficient accumulation due to accelerated elimination of the small-sized radioligand.

Related to this, recent study aimed to investigate whether an increase of Tz motifs by chelator scaffolding, i.e. multimerization, can improve the binding efficiency thereby improving imaging contrast. This could contribute in particular to the application of gallium-68 for pretargeted immuno-PET imaging. For this purpose we utilized the macrocyclic chelator Fusarinine C for the design of mono- and multimeric Tz-conjugates as presented in **Scheme I** for a proof-of-concept study, on potentially improved pretargeting for imaging with gallium-68 by applying multimerization. As a targeting vector, we chose non-internalizing anti-CD20 antibody rituximab (RTX) modified with TCO. Radiolabelling was conducted at room temperature within minutes and the <sup>68</sup>Ga-labelled conjugates showed reasonable hydrophilicity and excellent stability in human serum. However, protein binding remained comparable within the conjugates but was generally high. The <sup>68</sup>Ga-labelled multimeric conjugates showed a higher binding capacity towards TCO-motif bearing RTX. Furthermore, cell-binding studies revealed highly specific targeting properties and the binding of [<sup>68</sup>Ga]Ga-FSC-Tz multimers to CD20-expressing Raji cells increased with the number of Tz-motifs attached to the chelator. Imaging studies in a simplified pretargeting mouse model proved the trend

for improved targeting. We therefore conclude, that multimerization bears a great potential to improve IEDDA related pretargeting when short-lived PET-radioisotopes, particularly gallium-68, are used. Further investigations in established tumor models are warranted to confirm these promising findings.



**Scheme I.** Synthetic strategy for FSC-based tetrazine (Tz) conjugates [a: methanol and acetic anhydride (MetOH/Ac<sub>2</sub>O); b: DMF/DIPEA; c: EDTA]

## 2. Results

### 2.1. (Radio)Chemistry

FSC-based mono- and multimeric Tz-conjugates were accessible in a facile three-step synthesis to give the corresponding conjugates in good yields and high chemical purity (>95%; analytical RP-HPLC, UV absorption at  $\lambda = 220$  nm). Radiolabelling with gallium-68 was quantitative within minutes at RT, thus exhibiting fast labelling kinetics. Corresponding (radio-)RP-HPLC chromatograms are presented in **Figure S1**.

### 2.2. In vitro evaluation

Stability studies of  $^{68}\text{Ga}$ -labelled conjugates in fresh human serum and PBS as control revealed high stability as no major degradation was observed over a period of 4 h. Corresponding radio-RP-HPLC chromatograms are presented in **Figure S2**. The results of logD studies and the ability to bind to serum proteins of  $^{68}\text{Ga}$ -labelled conjugates is summarized in **Table 1**. They revealed suitable hydrophilicity with minor decrease when increasing the number of Tz residues. All conjugates showed very high protein binding with minor differences between mono- and multimeric [ $^{68}\text{Ga}$ ]Ga-Tz-ligands.


**Table 1.** Distribution coefficient (logD) and protein binding of  $^{68}\text{Ga}$ -labelled FSC-based Tz-conjugates

$^{68}\text{Ga}$ -labelled compound	logD (pH 7.4)	Protein binding (%)		
		1 h	2 h	4 h
Tz-monomer	$-1.64 \pm 0.02$	$61.8 \pm 0.2$	$63.8 \pm 2.1$	$64.0 \pm 1.4$
Tz-dimer	$-1.35 \pm 0.01$	$67.0 \pm 2.4$	$65.9 \pm 1.3$	$68.4 \pm 0.3$
Tz-trimer	$-1.00 \pm 0.06$	$70.5 \pm 0.7$	$69.5 \pm 0.4$	$67.8 \pm 0.4$

Data are presented as mean  $\pm$  SD (n = 3)

The non-internalizing anti-CD20 monoclonal antibody rituximab was modified with the TCO motif similar to a previously published procedure [15] and corresponding FACS analysis of CD20-expressing Raji cells incubated with both, TCO-modified and non-modified RTX showed high target specificity (**Figure S3**) demonstrating that the binding ability was not altered by the TCO modification.


The binding capacity of  $^{68}\text{Ga}$ -labelled mono- and multimeric Tz-ligands was assessed *via* competitive binding on immobilized RTX-TCO using the non-labelled conjugates as competitor and is presented in **Figure 1**. The binding of the [ $^{68}\text{Ga}$ ]Ga-Tz-monomer was reduced by 50 % at a competitor concentration of  $486 \pm 52$  nM when challenged with the non-labelled monomer, whereas the non-labelled dimer ( $112 \pm 6$  nM) and trimer ( $100 \pm 10$  nM) reduced the binding at significantly lower concentrations. The binding of the [ $^{68}\text{Ga}$ ]Ga-Tz-dimer was reduced by half at  $95 \pm 25$  nM in competition with its non-labelled counterpart and at a comparable concentration with the non-labelled trimer ( $92 \pm 15$  nM), whereas a decrease to 50 % was only achieved at a much higher concentration in competition with non-labelled monomer ( $865 \pm 263$  nM). Binding studies of the [ $^{68}\text{Ga}$ ]Ga-Tz-trimer showed a comparable trend as the non-labelled trimer reduced the binding by 50 % at  $147 \pm 49$  nM and the dimer at  $258 \pm 60$  nM while significantly higher amount of the monomer ( $2,987 \pm 1,664$  nM) was needed for 50 % binding reduction. Overall in all assays improved binding of di- and trimer over monomer was observed.



**Figure 1.** Competitive binding studies of [ $^{68}\text{Ga}$ ]Ga-Tz-monomer (A), [ $^{68}\text{Ga}$ ]Ga-Tz-dimer (B) and [ $^{68}\text{Ga}$ ]Ga-Tz-trimer (C) on immobilized RTX-TCO using the non-labelled counterparts as competitor.




The results of cell-binding studies on CD20-expressing Raji cells pre-treated with RTX or RTX-TCO prior to incubation with  $^{68}\text{Ga}$ -labelled Tz-ligands are presented in **Figure 2**. All  $^{68}\text{Ga}$ -labelled conjugates showed highly specific targeting properties as the amount of unspecific bound radioligand to RTX pre-treated Raji cells was negligible low ( $< 1\%$ ). The binding of  $^{68}\text{Ga}$ -labelled Tz-ligands on RTX-TCO bound Raji cells increased with the grade of multimerization and was  $4.01 \pm 0.24\%$  for  $[^{68}\text{Ga}]\text{Ga}$ -Tz-monomer,  $7.35 \pm 0.77\%$  for  $[^{68}\text{Ga}]\text{Ga}$ -Tz-dimer and  $15.93 \pm 0.88$  for  $[^{68}\text{Ga}]\text{Ga}$ -Tz-trimer, respectively.



**Figure 2.** Cell-binding studies of  $^{68}\text{Ga}$ -labelled FSC-based Tz-ligands on CD20-expressing Raji cells pre-treated with anti-CD20 antibody RTX (negative control, black bars) and its TCO modified counterpart (white bars).


## 2.2. In vivo evaluation

Biodistribution studies in non-tumour xenografted BALB/c mice 1 h after administration of the  $^{68}\text{Ga}$ -labelled Tz-ligands are shown in **Figure 3**. In general, accumulation in non-targeted tissue was significantly lower for the  $[^{68}\text{Ga}]\text{Ga}$ -Tz-monomer compared to the  $[^{68}\text{Ga}]\text{Ga}$ -Tz-trimer while the difference between the multimers was less pronounced. Particularly, the multimeric Tz-ligands showed slower blood clearance and higher accumulation in renal tissue compared to the monomeric conjugate but overall the conjugates showed low accumulation in non-targeted tissue and low retention in critical organs (e.g. muscle, bone).



**Figure 3.** Biodistribution studies of <sup>68</sup>Ga-labelled mono- and multimeric FSC-based pretargeting agents in normal BALB/c mice 1 h p.i. presented as percentage of total injected activity per gram tissue (n = 3).

Imaging studies using BALB/c mice i.m. injected with RTX and RTX-TCO as tumour surrogate 5 h prior to r.o. administration of the radioligand and imaging performed 90 min p.i. are presented in **Figure 4**. The results mainly confirmed the suitable *in vivo* distribution profile of FSC-based Tz-ligands radiolabelled with gallium-68 with main activity in kidneys and bladder. Moreover, the accumulation in RTX-TCO positive muscle tissue increased with ascending numbers of Tz motifs and was ~ 1 % for the [<sup>68</sup>Ga]Ga-Tz-monomer, ~ 2 % for the [<sup>68</sup>Ga]Ga-Tz-dimer and ~ 3 % for the [<sup>68</sup>Ga]Ga-Tz-trimer. Surprisingly, the accumulation in TCO negative tissue was also approximately 1 % with negligible differences between the different radioligands.



**Figure 4.** Static  $\mu$ PET/CT image of i.m. RTX(-TCO) pre-treated normal BALB/c mice 5 h after treatment and 90 min p.i. of the  $^{68}\text{Ga}$ -labelled Tz-monomer (a), Tz-dimer (b) and Tz-trimer (c). (1 = coronal slice; 2 = 3D volume rendered projections; both prone position).

### 3. Discussion

IEDDA-based pretargeting has become increasingly popular for molecular imaging as well as radioimmunotherapy over the past few years [16-21]. Despite recent advancements towards structural improvement of cyclen- and TACN-based Tz-probes [22,23] or the synthesis of TCO-bearing dendrimers [24], the design of targeting probes bearing multiple Tz-motifs for potentially improved pretargeting has scarcely been investigated. Devaraj and co-workers reported on polymer modified tetrazines (PMT) radiolabelled with fluorine-18 [25] and gallium-68 [26] for PET applications while Zlatni et al. recently demonstrated the targeting applicability for microbubbles bearing multiple Tz-motifs towards prostate specific membrane antigen for ultrasound related diagnostic purposes [15]. However, investigations on the use of small-sized multimeric Tz-ligands have not been reported yet.

FSC is a suitable chelating scaffold for PET radiometals, particularly gallium-68 and zirconium-89 [27,28], and its unique structural properties enable straight forward mono- and multimeric tracer design [29-32]. Therefore this novel chelator represented a very suitable scaffold for the synthesis of mono- and multimeric small-sized Tz-bearing probes for radiolabelling with gallium-68 to evaluate potential benefits for IEDDA-based pretargeting by increasing the number of Tz-residues. The resulting conjugates showed reasonable hydrophilicity and increasing the number of Tz-residues from one to three did not alter the water solubility too much, although being somewhat lower in comparison to linker modified monomeric conjugates [23]. Unexpectedly, all FSC-based Tz-conjugates showed high protein binding with negligible differences between the compounds. This can be related to the introduction of the pegylated Tz residue as non-modified  $^{68}\text{Ga}$ -labelled FSC-based precursors showed a protein binding < 3 % (Kaepookum et al. unpublished results). This phenomenon has not been reported for monomeric DOTA- and TACN-based derivatives [22,23] and might be disadvantageous slowing down the distribution of the tracer to the TCO-interaction site. However *in vivo* results did not really reveal a major problem with too slow pharmacokinetics as the washout from non-targeted tissue was sufficiently rapid. Competitive binding assessments showed significantly reduced binding of [ $^{68}\text{Ga}$ ]Ga-Tz-monomer by a factor of five when challenged with the multimeric conjugates in comparison with the non-labelled monomer. This corresponded with the



significantly higher amounts of Tz-monomer needed, 8 to 20 fold respectively, to reduce the binding of the  $^{68}\text{Ga}$ -labelled multimers by 50 %, thus indicating that the binding capacity increased with the number of Tz residues. This was substantiated by the results of the cell binding studies as the binding to CD20-expressing Raji cells increased by a factor of 1.8 for the [ $^{68}\text{Ga}$ ]Ga-Tz-dimer and 3.9 for the [ $^{68}\text{Ga}$ ]Ga-Tz-trimer in comparison to the [ $^{68}\text{Ga}$ ]Ga-Tz-monomer. Biodistribution studies in non-tumour xenografted healthy BALB/c mice indicated suitable pharmacokinetics and showed a multimerization typical profile exhibiting slower blood clearance and increased kidney retention, similar to prior findings with the FSC-scaffold [31,32]. Imaging studies using a tumour surrogate model confirmed this trend and demonstrated increased binding of the  $^{68}\text{Ga}$ -labelled multimeric Tz-conjugates. The accumulation in RTX-TCO pretreated muscle tissue doubled for the [ $^{68}\text{Ga}$ ]Ga-Tz-dimer and was 3-fold higher for the [ $^{68}\text{Ga}$ ]Ga-Tz-trimer compared to the [ $^{68}\text{Ga}$ ]Ga-Tz-monomer.

Regarding imaging in living mice there was a clear improvement of target specific accumulation when switching from mono- to multimers. However, the use of our simplified tumour surrogate animal model requires further investigations in established animal models to address the limitations of this study:

1.) The accumulation in non-targeted tissue, i.e. i.m. injection of RTX resulted to be ~ 1 %. This effect was even more pronounced when choosing a shorter time interval of 2 h between i.m. administration of the mAb and radioligand injection (data not shown) and was only seen at the injection site but not in other tissue generally. We speculate that this is related to the injection of the antibody leading to tissue damage with increased tissue permeability and unspecific accumulation of the radioligand.

2.) Intravenously injected mAb stimulates accumulation at the target interaction site but a non-negligible amount remains in circulation increasing the background signal when administering the radioligand. In order to reduce this amount, high molecular weight TCO-scavenger molecules exhibiting low vascular permeability (clearing agents) have been established with great success improving target-to-background (TTB) ratios significantly [33,34]. The need for clearing agents was completely neglected in this study and we are fully aware that our animal model does not reflect the real situation regarding TTB ratios.

In summary, we could show that FSC is a suitable scaffold for the design of multimeric Tz-conjugates for radiolabelling with gallium-68. Although multimeric Tz-ligands exhibited significant improvements towards IEDDA-based pretargeting additional studies in tumour models are warranted to explore the full potential of this promising concept. Furthermore, a highly interesting therapeutic approach is the release of drugs directly at the interaction site from antibody-drug conjugates (ADCs) mediated *via* IEDDA reaction between Tz and TCO [35,37] and it might be of interest for future perspectives if multimeric Tz-conjugates can boost the release of drugs improving this highly promising “click-to-release” strategy.

## 4. Materials and Methods

### 4.1. Instrumentation

#### 4.1.1. Analytical [radio]-RP-HPLC

Reversed-phase high-performance liquid chromatography analysis was performed with following instrumentation: UltiMate 3000 RS UHPLC pump, UltiMate 3000 autosampler, Ultimate 3000 column compartment (25 °C oven temperature), UltiMate 3000 Variable Wavelength Detector (Dionex, Germering, Germany; UV detection at  $\lambda = 220$  nm) a radio detector (GabiStar, Raytest; Straubenhardt, Germany), Jupiter 5 $\mu\text{m}$  C<sub>18</sub> 300 Å 150 × 4.6 mm (Phenomenex Ltd. Aschaffenburg, Germany) column with acetonitrile (ACN)/H<sub>2</sub>O/ 0.1 % trifluoroacetic acid (TFA) as mobile phase; flow rate of 1 mL/min; gradient: 0.0–1.0 min 10 % ACN, 1.0–12.0 min 10–60 % ACN, 13.0–15.0 min 60–80 % ACN, 15.0–16.0 min 80–10 % ACN, 16.0–20.0 min 10 % ACN.

#### 4.1.2. Preparative RP-HPLC

Sample purification *via* RP-HPLC was carried out as follows: Gilson 322 Pump with a Gilson UV/VIS-155 detector (UV detection at  $\lambda = 220$  nm) using a PrepFC™ automatic fraction collector (Gilson, Middleton, WI, USA), Eurosil Bioselect Vertex Plus 30 x 8 mm 5  $\mu\text{m}$  C<sub>18A</sub> 300 Å pre-column and Eurosil Bioselect Vertex Plus 300 x 8 mm 5  $\mu\text{m}$  C<sub>18A</sub> 300 Å column (Knauer, Berlin, Germany) and following ACN/H<sub>2</sub>O/0.1 % TFA gradients with a flow rate of 2 mL/min: gradient A: 0.0–5.0 min 0 % ACN, 5.0–35.0 min 0–50 % ACN, 35.0–38.0 min 50 % ACN, 38.0–40.0 min 50–0 % ACN. Gradient B: 0.0–5.0 min 10 % ACN, 5.0–40.0 min 10–60 % ACN, 41.0–45.0 min 60 % ACN, 46.0–50.0 min. 60–80 % ACN, 51.0–55.0 min 80–10 % ACN.

#### 4.1.3. MALDI-TOF MS

Mass spectrometry was conducted on a Bruker microflex™ bench-top MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) with a 20 Hz laser source. Sample preparation was performed according to dried-droplet method on a micro scout target (MSP96 target ground steel BC, Bruker Daltonics) using  $\alpha$ -cyano-4-hydroxycinnamic acid (HCCA, Sigma-Aldrich, Handels GmbH, Vienna, Austria) as matrix and Flex Analysis 2.4 software was used for processing of the recorded data.

### 4.2 Synthesis

#### 4.2.1. General information

All chemicals and solvents were purchased as reagent grade from commercial sources unless otherwise stated. *Trans*-cyclooctene-NHS ester and Tetrazine-PEG<sub>5</sub>-NHS ester were bought from Click Chemistry Tools (Scottsdale, AZ, USA). Rituximab (MabThera®, Roche Pharma AG, Switzerland) was of pharmaceutical grade and was a kind gift from the University Hospital of Innsbruck.

#### 4.2.2. [Fe]Fusarinine C ([Fe]FSC)

The cyclic siderophore Fusarinine C (FSC) was obtained from iron deficient fungal culture and the extraction of FSC was conducted with a slightly modified method as described before [38]. Briefly, 1000 mL of iron saturated culture media was flushed through a C<sub>18</sub>-Reveleris flash cartridge (40  $\mu\text{m}$ , 12 g; Grace, Maryland, USA) by using a REGLO tubing pump (Type ISM795, Ismatec SA, Glattbrugg-Zurich, Switzerland) with a flow rate of 10 mL/min. The cartridge fixed [Fe]FSC was washed with 50 mL of water and eluted afterwards with 50 mL H<sub>2</sub>O/ACN (20/80 % v/v). After evaporation to dryness ~ 300 mg [Fe]FSC were obtained as red-brown coloured solid in high purity (> 90 %). Analytical data: RP-HPLC  $t_{\text{R}} = 6.95$  min; MALDI TOF-MS:  $m/z$  [M + H]<sup>+</sup> = 779.93 [C<sub>33</sub>H<sub>51</sub>FeN<sub>6</sub>O<sub>12</sub>; exact mass: 779.63 (calculated)].

#### 4.2.3. Acetylation of [Fe]FSC

[Fe]FSC was dissolved in methanol to a final concentration of 30 mg/mL (38.5 mM). An aliquot of 300  $\mu\text{L}$  was reacted with 10  $\mu\text{L}$  of acetic anhydride for 5 min at room temperature (RT) under vigorously shaking followed by subsequent purification of the resulting mixture of mono-, di- and triacetylfusarinine C *via* preparative RP-HPLC using gradient A to obtain *N*-monoacetylfusarinine C ([Fe]MAFC,  $t_{\text{R}} = 20.1$  min) and *N,N'*-diacetylfusarinine C ([Fe]DAFC,  $t_{\text{R}} = 24.5$  min). Analytical data: [Fe]MAFC: RP-HPLC  $t_{\text{R}} = 7.67$  min; MALDI TOF-MS:  $m/z$  [M+H]<sup>+</sup> = 822.04 [C<sub>35</sub>H<sub>53</sub>FeN<sub>6</sub>O<sub>13</sub>; exact mass: 821.67 (calculated)]. [Fe]DAFC: RP-HPLC  $t_{\text{R}} = 8.49$  min; MALDI TOF-MS:  $m/z$  [M+H]<sup>+</sup> = 864.02 [C<sub>37</sub>H<sub>55</sub>FeN<sub>6</sub>O<sub>14</sub>; exact mass: 863.71 (calculated)].

#### 4.2.4. Conjugation of Tetrazine-PEG<sub>5</sub> motif

Corresponding amounts of iron protected FSC (1.0 mg, 1.28  $\mu\text{mol}$ ), MAFC (2.0 mg, 2.43  $\mu\text{mol}$ ) and DAFC (2.0 mg, 2.32  $\mu\text{mol}$ ) were dissolved in 500  $\mu\text{L}$  anhydrous DMF and after addition of 1.5 to 3.5 equivalents of Tetrazine-PEG<sub>5</sub>-NHS ester pH 9.0 was adjusted using DIPEA and the reaction mixtures were maintained for 4 hours at RT.

#### 4.2.5. Demetallation

For the purpose of iron removal the organic solvent was evaporated, corresponding conjugates were dissolved in 1 mL H<sub>2</sub>O/ACN solvent 50 % (v/v) and 1 mL of aqueous Na<sub>2</sub>EDTA solution (200 mM) was added. The resulting mixtures were stirred for 4 h at ambient temperature followed by preparative RP-HPLC purification to give slightly to intensively pink coloured, iron free FSC-based Tz-conjugates after lyophilisation.

- DAFC-PEG<sub>5</sub>-Tz (= Tz-**monomer**): 2.35 mg [1.81 μmol, 78 %], gradient B (t<sub>R</sub> = 31.1 min); Analytical data: RP-HPLC t<sub>R</sub> = 11.5 min; MALDI TOF-MS: m/z [M+H]<sup>+</sup> = 1303.95 [C<sub>60</sub>H<sub>89</sub>N<sub>11</sub>O<sub>21</sub>; exact mass: 1300.41 (calculated)]
- MAFC-(PEG<sub>5</sub>-Tz)<sub>2</sub> (= Tz-**dimer**): 3.65 mg [2.09 μmol, 86 %], gradient B (t<sub>R</sub> = 35.3 min); Analytical data: RP-HPLC t<sub>R</sub> = 12.5 min; MALDI TOF-MS: m/z [M+H]<sup>+</sup> = 1748.25 [C<sub>81</sub>H<sub>118</sub>N<sub>16</sub>O<sub>27</sub>; exact mass: 1747.89 (calculated)]
- FSC-(PEG<sub>5</sub>-Tz)<sub>3</sub> (= Tz-**trimer**): 1.68 mg [0.77 μmol, 60 %], gradient B (t<sub>R</sub> = 37.9 min); Analytical data: RP-HPLC t<sub>R</sub> = 13.2 min; MALDI TOF-MS: m/z [M+H]<sup>+</sup> = 2200.20 [C<sub>102</sub>H<sub>147</sub>N<sub>21</sub>O<sub>33</sub>; exact mass: 2195.38 (calculated)]

#### 4.2.6. Modification of Rituximab (RTX)

Rituximab was obtained in solution (Mabthera<sup>®</sup>, 10 mg/mL) and a PD-10 (GE Healthcare Vienna, Austria) size exclusion column was used for buffer exchange according to manufacturer's protocol to give RTX in 0.1 M NaHCO<sub>3</sub> solution (7 mg/mL). For the conjugation of *trans*-cyclooctene (TCO), 2 mL of the RTX solution were mixed with 20 molar equivalent of TCO-NHS ester dissolved in DMSO and the reaction was stirred for 30 min at ambient temperature followed by incubation overnight at 4 °C under light exclusion. Subsequently, the modified antibody (RTX-TCO) was purified using size exclusion chromatography to give 10 mg of RTX-TCO dissolved in PBS. To obtain a non-modified RTX counterpart as negative control, the antibody was treated following the same procedure as described above without adding TCO-NHS ester.

#### 4.3. Fluorescence activated cell-sorting (FACS)

Flow cytometric analysis of CD20 expression was evaluated on Raji cells adjusted to 5x10<sup>5</sup> cells/sample in DMEM (including 10% FCS, 1% Pen/Strep). To avoid signals from non-specific binding, cells were incubated with FC-Block (containing CD16/CD32 (1:200), e-Bioscience) for 15 min at 4°C. Following antibodies were used: RTX-TCO and RTX, both at 20 μM (f. c.). As secondary antibody a APC-labelled anti-human IgG Fc (clone: HP6017; BioLegend) at a dilution of 1:100 was used. Antibodies were incubated for at least 15 min at 4°C. FACS analysis was performed on BD LSRFortessa<sup>™</sup> (Cell Analyzer, BD Bioscience). As internal control samples unstained or stained with either primary or secondary antibodies were analyzed. FACS-data were analyzed by FlowJo v10 software.

#### 4.4. Radiolabelling of FSC-based Tz-conjugates with gallium-68

Gallium-68 was obtained as [<sup>68</sup>Ga]GaCl<sub>3</sub> (gallium chloride) by fractioned elution of a <sup>68</sup>Ge/<sup>68</sup>Ga-generator (IGG100, nominal activity 1100 MBq, Eckert & Ziegler, Berlin, Germany) with 0.1 M hydrochloric acid (HCl, Rotem Industries Ltd., Beer-Sheva, Israel). Hereafter, 500 μL of eluate (100 MBq) were mixed with 100 μL sodium acetate solution (1.14 M) to give a pH of 4.5 followed by addition of 10 μg (4.55-7.68 nmol) of corresponding FSC-Tz conjugate. After 5 min incubation at RT the radiolabelling success was analyzed using radio-RP-HPLC.

#### 4.5. In vitro characterization.

#### 4.5.1. Distribution coefficient (logD)

To determine the distribution of the  $^{68}\text{Ga}$ -labelled conjugates between an organic (octanol) and aqueous (PBS) layer, aliquots (50  $\mu\text{L}$ ) of the tracers ( $\sim 5 \mu\text{M}$ ) were diluted in 1 mL of octanol/PBS (1:1, v/v). The mixture was vortexed at 1400 rpm (MS 3 basic vortexer, IKA, Staufen, Germany) for 15 min at RT followed by centrifugation for 2 min at 4500 rpm. Subsequently, aliquots (50  $\mu\text{L}$ ) of both layers were collected and measured in the gamma counter (Wizard2 3", Perkin Elmer, Waltham, MA, USA) followed by logD calculation ( $n = 3$ , six replicates).

#### 4.5.2. Protein Binding

Serum protein binding was determined using Sephadex G-50 (GE Healthcare Vienna, Austria) Chalfont, UK size exclusion chromatography. Therefore aliquots (50  $\mu\text{L}$ ,  $n = 3$ ) of the radioligand solution ( $\sim 10 \mu\text{M}$ ) were incubated in 450  $\mu\text{L}$  PBS as control and 450  $\mu\text{L}$  freshly prepared human serum and were kept at 37 °C. After 1, 2, and 4 h aliquots (25  $\mu\text{L}$ ) were transferred to the column (MicroSpin G-50, GE Healthcare, Vienna, Austria) and after centrifugation (2 min, 2000 rcf) the column containing the free conjugate and the eluate containing the protein-bound conjugate were measured in the gamma counter followed by calculating the percentage between both fractions.

#### 4.5.3. Stability studies in human serum

To investigate on the stability of the radioligands in human serum 50  $\mu\text{L}$  of the radiolabelling solution ( $\sim 10 \mu\text{M}$ ,  $n = 2$ ) were mixed with 950  $\mu\text{L}$  freshly prepared serum and 950  $\mu\text{L}$  PBS as control and the mixtures were maintained at 37 °C. At dedicated time points, 1, 2 and 4 h respectively, aliquots (100  $\mu\text{L}$ ) were mixed with 0.1 % TFA/ACN, centrifuged for 2 min at  $18 \times 10^3$  rcf. The supernatant was diluted with  $\text{H}_2\text{O}$  (1:1, v/v) and analyzed by analytical RP-HPLC for decomposition.

#### 4.5.4. Competitive Binding Assay

Binding on immobilized RTX-TCO was conducted using high protein-binding capacity Nunc MaxiSorp™ 96-well plates (Thermo Fisher Scientific, Vienna, Austria). Coating was performed by adding 20  $\mu\text{g}$  of antibody (RTX or RTX-TCO) dissolved in 100  $\mu\text{L}$  coating buffer (0.1 M  $\text{NaHCO}_3$ , pH 8.5) to each well and after 2 h incubation at RT the plate was left at 4 °C overnight both under light exclusion. After removal of the coating solution 200  $\mu\text{L}$  of blocking buffer (1 % BSA in PBS) was added, left for 1 h at room temperature followed by washing each well twice with 200  $\mu\text{L}$  binding buffer (0.1 % BSA in PBS). Hereafter, the radioligand was mixed with increasing concentrations of the competitor (= non-labelled conjugate) both diluted in binding buffer and 100  $\mu\text{L}$  of the mixture was added to each well. After 30 min at RT the supernatant was removed, each well was washed three times with 150  $\mu\text{L}$  binding buffer and the coating film was finally detached with  $2 \times 150 \mu\text{L}$  of hot (80 °C) 2 N sodium hydroxide (NaOH). The NaOH fraction was taken for gamma counter measurement to determine the percentage of binding compared to the standard followed by non-linear curve fitting using Origin 6.1 software (Northampton, MA, USA) to calculate the apparent half maximum inhibitory concentration of the competitor ( $n = 3$ , 4 replicates).

#### 4.5.5. Cell binding

The humanoid lymphoblast-like CD20-expressing B-lymphocyte cells (Raji cells) were purchased from American Type Culture Collection (ATCC, Manassas, Virginia, USA). The cells were seeded in tissue culture flasks (Cellstar; Greiner Bio-One, Kremsmuenster, Austria) using RPMI-1640 medium supplemented with fetal bovine serum (FBS) to a final concentration of 10 % (v/v). For cell binding studies  $10 \times 10^6$  cells were washed twice with fresh media, diluted with PBS to a final concentration of  $1 \times 10^6$  cells per mL and 500  $\mu\text{L}$  of cell suspension was transferred to Eppendorf



tubes. Hereafter, 50  $\mu\text{L}$  of RTX-TCO or non-modified RTX as negative control (both 0.5  $\mu\text{M}$ ) were added and the cell suspension was maintained at 37 °C under gentle shaking. After 1 h the suspension was centrifuged (2 min,  $11 \times 10^3$  rcf), the supernatant was discarded, the cells were washed twice and finally resuspended with 450  $\mu\text{L}$  PBS. Subsequently, 50  $\mu\text{L}$  of the radioligand solution (22 nM in PBS) was added and the suspension was incubated for 30 min at 37 °C. After centrifugation and two washing steps with 600  $\mu\text{L}$  PBS, the cells were resuspended in 500  $\mu\text{L}$  PBS and transferred to polypropylene vials for gamma counter measurement followed by calculation from cell-associated activity in comparison to the standard ( $n = 3$ , six replicates).

#### 4.6. *In vivo* characterization.

##### 4.6.1. Ethics statement.

All animal experiments were performed in accordance with regulations and guidelines of the Austrian animal protection laws and the Czech Animal Protection Act (No. 246/1992), with approval of the Austrian Ministry of Science (BMWF-66.011/0161-WF/V/3b/2016) and with the approval of the Czech Ministry of Education, Youth, and Sports (MSMT-18724/2016-2), and the institutional Animal Welfare Committee of the Faculty of Medicine and Dentistry of Palacky University in Olomouc.


##### 4.6.2. Biodistribution studies

Biodistribution of  $^{68}\text{Ga}$ -labelled conjugates was conducted in healthy 5-week-old female BALB/c mice (Charles River Laboratories, Sulzfeld, Germany). Animals ( $n = 3$ ) were injected *via* lateral tail vein with 1 nmol of conjugate and a total activity of approximately 6 MBq. Mice were sacrificed by cervical dislocation 1 h p.i. followed by collection of the main organs and tissue, subsequent gamma counter measurement and calculation of the percentage of injected activity per gram tissue (% IA/g).


##### 4.6.3. Imaging studies

MicroPET/CT images were acquired with an Albira PET/SPECT/CT small animal imaging system (Bruker Biospin Corporation, Woodbridge, CT, USA). Mice were pre-treated by intramuscular (i.m.) injection of 50  $\mu\text{L}$  of RTX-TCO to the left hind muscle and 50  $\mu\text{L}$  of RTX to the right hind muscle. Pre-treated mice were retro-orbitally (r.o.) injected with radiolabelled tracer in a dose of 5-10 MBq corresponding to 1-2  $\mu\text{g}$  of conjugate per animal 5 h after the pre-treatment. Anaesthetized (2 % isoflurane (FORANE, Abbott Laboratories, Abbott Park, IL, USA)) animals were placed in a prone position in the Albira system before the start of imaging. Static PET/CT images were acquired over 30 min starting 90 min p.i. A 10-min PET scan (axial FOV 148 mm) was performed, followed by a double CT scan (axial FOV 65 mm, 45 kVp, 400  $\mu\text{A}$ , at 400 projections). Scans were reconstructed with the Albira software (Bruker Biospin Corporation, Woodbridge, CT, USA) using the maximum likelihood expectation maximization (MLEM) and filtered backprojection (FBP) algorithms. After reconstruction, acquired data was viewed and analyzed with PMOD software (PMOD Technologies Ltd., Zurich, Switzerland). 3D volume rendered images were obtained using VolView software (Kitware, Clifton Park, NY, USA).


**Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1)



**Figure S1.** Representative RP-HPLC chromatograms of mono- and multimeric FSC-Tz conjugates (A, UV-Vis chromatograms) and their  $^{68}\text{Ga}$ -labelled counterparts (B, radio-chromatograms)



**Figure S2.** Representative radio-RP-HPLC chromatograms of the stability assessment of  $^{68}\text{Ga}$ -labelled mono- and multimeric FSC-Tz conjugates incubated with fresh human serum (A) and PBS (B).



**Figure S3.** Fluorescence-activated cell sorting of unstained Raji cells, RTX, RTX-TCO, secondary antibody (APC), RTX + APC and RTX-TCO + APC (order from left to right).

**Author Contributions:** L.V. carried out the synthesis of FSC-Tz conjugates under guidance of B.M. and both provided the corresponding part of the manuscript; D.S. evaluated the protocol for radiolabelling with gallium-68, reviewed the literature, summarized the results and has written the major part of the manuscript; C.R. performed cell culture, animal housing and animal care; S.M. modified the antibody and evaluated the radiolabelled conjugates *in vitro* as well as *in vivo*. K.S. provided the Raji cells and carried out FACS analysis of the antibodies. M.P. evaluated the tumour-surrogate model and performed *in vivo* imaging studies. C.D. was responsible for conceptualization, funding acquisition, project administration and supervision.

**Funding:** This research was funded by the Austrian Science Foundation (FWF) grant P 25899-B23 and by the Czech Ministry of Education Youth and Sports grant LO1304.

**Acknowledgments:** We gratefully acknowledge the staff from the hospital pharmacy for supplying us with Rituximab, the Austrian Science Foundation (FWF) and the Czech Ministry of Education Youth and Sports for funding.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

**Abbreviations.** ACN, acetonitrile; BSA, bovine serum albumin; CD, cluster of differentiation; DAFC, *N,N'*-diacetylfusarinine C; DIPEA, *N,N*-diisopropylamine; DMF, *N,N*-dimethylformamide; EDTA, ethylenediaminetetraacetic acid; FSC, fusarinine C; IEDDA, inverse electron-demand Diels-Alder; i.m., intramuscular; mAb, monoclonal antibody; MAFC, *N*-monoacetylfusarinine C; NHS, *N*-hydroxysuccinimide; p.i., post injection; PBS, phosphate buffered saline; PET/CT, positron emission computed tomography; r.o., retro-



orbitally; RP-HPLC, reversed phase high performance liquid chromatography; RT, room temperature; RTX, rituximab; TCO, *trans*-cyclooctene; TFA, trifluoroacetic acid; Tz, tetrazine.

## References

1. Henricks, L. M.; Schellens, J. H. M.; Huitema, A. D. R.; Beijnen, J. H. The use of combinations of monoclonal antibodies in clinical oncology. *Cancer Treat. Rev.* **2015**, *41*, 859–867, doi:10.1016/j.ctrv.2015.10.008.
2. Zhang, H.; Chen, J. Current status and future directions of cancer immunotherapy. *J. Cancer* **2018**, *9*, 1773–1781, doi:10.7150/jca.24577.
3. Knowles, S. M.; Wu, A. M. Advances in immuno-positron emission tomography: Antibodies for molecular imaging in oncology. *J. Clin. Oncol.* **2012**, *30*, 3884–3892, doi:10.1200/JCO.2012.42.4887.
4. Van De Watering, F. C. J.; Rijpkema, M.; Perk, L.; Brinkmann, U.; Oyen, W. J. G.; Boerman, O. C. Zirconium-89 labeled antibodies: A new tool for molecular imaging in cancer patients. *Biomed Res. Int.* **2014**, Article ID 203601, 1–13, doi:10.1155/2014/203601.
5. Jauw, Y. W. S.; Menke-van der Houven van Oordt, C. W.; Hoekstra, O. S.; Hendrikse, H. N.; Vugts, D. J.; Zijlstra, J. M.; Huisman, M. C.; van Dongen, G. A. M. S. Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: What can we learn from initial clinical trials? *Front. Pharmacol.* **2016**, *7*, 1–15, doi:10.3389/fphar.2016.00131.
6. Patra, M.; Zarschler, K.; Pietzsch, H.-J.; Stephan, H.; Gasser, G. New insights into the pretargeting approach to image and treat tumours. *Chem. Soc. Rev.* **2016**, *45*, 6415–31, doi:10.1039/C5CS00784D.
7. Bailly, C.; Bodet-Milin, C.; Rousseau, C.; Faivre-Chauvet, A.; Kraeber-Bodéré, F.; Barbet, J. Pretargeting for imaging and therapy in oncological nuclear medicine. *EJNMMI Radiopharm. Chem.* **2017**, *2*, 1-14, doi:10.1186/s41181-017-0026-8.
8. Altai, M.; Membreno, R.; Cook, B.; Tolmachev, V.; Zeglis, B. M. Pretargeted Imaging and Therapy. *J. Nucl. Med.* **2017**, *58*, 1553–59, doi:10.2967/jnumed.117.189944.
9. Karver, M. R.; Weissleder, R.; Hilderbrand, S. A. Synthesis and evaluation of a series of 1,2,4,5-tetrazines for bioorthogonal conjugation. *Bioconjug. Chem.* **2011**, *22*, 2263–2270, doi:10.1021/bc200295y.
10. Oliveira, B. L.; Guo, Z.; Bernardes, G. J. L. Inverse electron demand Diels–Alder reactions in chemical biology. *Chem. Soc. Rev.* **2017**, *46*, 4895–4950, doi:10.1039/C7CS00184C.
11. Zeglis, B. M.; Sevak, K. K.; Reiner, T.; Mohindra, P.; Carlin, S. D.; Zanzonico, P.; Weissleder, R.; Lewis, J. S. A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels–Alder Click Chemistry. *J. Nucl. Med.* **2013**, *54*, 1389–96, doi:10.1109/TMI.2012.2196707.Separate.
12. Cook, B. E.; Adumeau, P.; Membreno, R.; Carnazza, K. E.; Brand, C.; Reiner, T.; Agnew, B. J.; Lewis, J. S.; Zeglis, B. M. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. *Bioconjug. Chem.* **2016**, *27*, 1789–1795, doi:10.1021/acs.bioconjchem.6b00235.

13. Meyer, J. P.; Houghton, J. L.; Kozlowski, P.; Abdel-Atti, D.; Reiner, T.; Pillarsetty, N. V. K.; Scholz, W. W.; Zeglis, B. M.; Lewis, J. S. <sup>18</sup>F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. *Bioconjug. Chem.* **2016**, *27*, 298–301, doi:10.1021/acs.bioconjchem.5b00504.
14. Denk, C.; Svatunek, D.; Mairinger, S.; Stanek, J.; Filip, T.; Matscheko, D.; Kuntner, C.; Wanek, T.; Mikula, H. Design, Synthesis, and Evaluation of a Low-Molecular-Weight <sup>11</sup>C-Labeled Tetrazine for Pretargeted PET Imaging Applying Bioorthogonal in Vivo Click Chemistry. *Bioconjug. Chem.* **2016**, *27*, 1707–1712, doi:10.1021/acs.bioconjchem.6b00234.
15. Zlitni, A.; Yin, M.; Janzen, N.; Chatterjee, S.; Lisok, A.; Gabrielson, K. L.; Nimmagadda, S.; Pomper, M. G.; Foster, F. S.; Valliant, J. F. Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. *PLoS One* **2017**, *12*, 1–17, doi:10.1371/journal.pone.0176958.
16. Knight, J. C.; Cornelissen, B. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. *Am. J. Nucl. Med. Mol. Imaging* **2014**, *4*, 96–113.
17. Rossin, R.; Verkerk, P. R.; Van Den Bosch, S. M.; Vulders, R. C. M.; Verel, I.; Lub, J.; Robillard, M. S. In vivo chemistry for pretargeted tumor imaging in live mice. *Angew. Chemie - Int. Ed.* **2010**, *49*, 3375–3378, doi:10.1002/anie.200906294.
18. Billaud, E. M. F.; Belderbos, S.; Cleeren, F.; Maes, W.; Van De Wouwer, M.; Koole, M.; Verbruggen, A.; Himmelreich, U.; Geukens, N.; Bormans, G. Pretargeted PET Imaging Using a Bioorthogonal <sup>18</sup>F-Labeled trans-Cyclooctene in an Ovarian Carcinoma Model. *Bioconjug. Chem.* **2017**, *28*, 2915–2920, doi:10.1021/acs.bioconjchem.7b00635.
19. Keinänen, O.; Fung, K.; Pourat, J.; Jallinoja, V.; Vivier, D.; Pillarsetty, N. V. K.; Airaksinen, A. J.; Lewis, J. S.; Zeglis, B. M.; Sarparanta, M. Pretargeting of internalizing trastuzumab and cetuximab with a <sup>18</sup>F-tetrazine tracer in xenograft models. *EJNMMI Res.* **2017**, *7*, 1–12, doi:10.1186/s13550-017-0344-6.
20. Houghton, J. L.; Membreno, R.; Abdel-Atti, D.; Cunanan, K. M.; Carlin, S.; Scholz, W. W.; Zanzonico, P. B.; Lewis, J. S.; Zeglis, B. M. Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand Diels- Alder click chemistry. *Mol. Cancer Ther.* **2017**, *16*, 124–133, doi:10.1126/science.1249098.Sleep.
21. Membreno, R.; Cook, B. E.; Fung, K.; Lewis, J. S.; Zeglis, B. M. Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. *Mol. Pharm.* **2018**, *15*, 1729–1734, doi:10.1021/acs.molpharmaceut.8b00093.
22. Lämpchen, T.; Rossin, R.; van Mourik, T. R.; Gruntz, G.; Hoeben, F. J. M.; Versteegen, R. M.; Janssen, H. M.; Lub, J.; Robillard, M. S. DOTA-tetrazine probes with modified linkers for tumor pretargeting. *Nucl. Med. Biol.* **2017**, *55*, 19–26, doi:10.1016/j.nucmedbio.2017.09.001.
23. Meyer, J. P.; Kozlowski, P.; Jackson, J.; Cunanan, K. M.; Adumeau, P.; Dilling, T. R.; Zeglis, B. M.; Lewis, J. S. Exploring Structural Parameters for Pretargeting Radioligand Optimization. *J. Med. Chem.* **2017**, *60*, 8201–8217, doi:10.1021/acs.jmedchem.7b01108.

24. Cook, B. E.; Membreno, R.; Zeglis, B. M. A Dendrimer Scaffold for the Amplification of in Vivo Pretargeting Ligations. *Bioconjug. Chem.* **2018**, *29*, 2734–2740, doi:10.1021/acs.bioconjchem.8b00385.
25. Devaraj, N. K.; Thurber, G. M.; Keliher, E. J.; Marinelli, B.; Weissleder, R. Reactive polymer enables efficient in vivo bioorthogonal chemistry. *Proc. Natl. Acad. Sci.* **2012**, *109*, 4762–4767, doi:10.1073/pnas.1113466109.
26. Nichols, B.; Qin, Z.; Yang, J.; Vera, D. R.; Devaraj, N. K. <sup>68</sup>Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers. *Chem. Commun.* **2014**, *50*, 5215–5217, doi:10.1039/C3CC49530B.
27. Zhai, C.; Summer, D.; Rangger, C.; Haas, H.; Haubner, R.; Decristoforo, C. Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68. *J. Label. Compd. Radiopharm.* **2015**, *58*, 209–214, doi:10.1002/jlcr.3286.
28. Summer, D.; Garousi, J.; Oroujeni, M.; Mitran, B.; Andersson, K. G.; Vorobyeva, A.; Löfblom, J.; Orlova, A.; Tolmachev, V.; Decristoforo, C. Cyclic versus Noncyclic Chelating Scaffold for <sup>89</sup>Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. *Mol. Pharm.* **2018**, *15*, 175–185, doi:10.1021/acs.molpharmaceut.7b00787.
29. Knetsch, P. A.; Zhai, C.; Rangger, C.; Blatzer, M.; Haas, H.; Kaeopookum, P.; Haubner, R.; Decristoforo, C. [<sup>68</sup>Ga]FSC-(RGD)<sub>3</sub> a trimeric RGD peptide for imaging  $\alpha_v\beta_3$  integrin expression based on a novel siderophore derived chelating scaffold-synthesis and evaluation. *Nucl. Med. Biol.* **2015**, *42*, 115–122, doi:10.1016/j.nucmedbio.2014.10.001.
30. Zhai, C.; Summer, D.; Rangger, C.; Franssen, G. M.; Laverman, P.; Haas, H.; Petrik, M.; Haubner, R.; Decristoforo, C. Novel Bifunctional Cyclic Chelator for <sup>89</sup>Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates. *Mol. Pharm.* **2015**, *12*, 2142–50, doi:10.1021/acs.molpharmaceut.5b00128.
31. Summer, D.; Rangger, C.; Klingler, M.; Laverman, P.; Franssen, G. M.; Lechner, B. E.; Orasch, T.; Haas, H.; von Guggenberg, E.; Decristoforo, C. Exploiting the concept of multivalency with <sup>68</sup>Ga- and <sup>89</sup>Zr-labelled Fusarinine C-minigastrin bioconjugates for targeting CCK2R expression. *Contrast Media Mol. Imaging* **2018**, Article ID 3171794, 1–12, doi:org/10.1155/2018/3171794.
32. Summer, D.; Kroess, A.; Woerndle, R.; Rangger, C.; Klingler, M.; Haas, H.; Kremser, L.; Lindner, H. H.; Guggenberg, E. Von; Decristoforo, C. Multimerization results in formation of re- bindable metabolites : A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression. *PLoS One* **2018**, 1–18, doi:org/10.1371/journal.pone.0201224.
33. Rossin, R.; Lappchen, T.; van den Bosch, S. M.; Laforest, R.; Robillard, M. S. Diels-Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody. *J. Nucl. Med.* **2013**, *54*, 1989–1995, doi:10.2967/jnumed.113.123745.
34. Meyer, J. P.; Tully, K. M.; Jackson, J.; Dilling, T. R.; Reiner, T.; Lewis, J. S. Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. *Bioconjug. Chem.* **2018**, *29*, 538–545, doi:10.1021/acs.bioconjchem.8b00028.

35. Rossin, R.; Van Duijnhoven, S. M. J.; Ten Hoeve, W.; Janssen, H. M.; Kleijn, L. H. J.; Hoeben, F. J. M.; Versteegen, R. M.; Robillard, M. S. Triggered Drug Release from an Antibody-Drug Conjugate Using Fast “click-to-Release” Chemistry in Mice. *Bioconjug. Chem.* **2016**, *27*, 1697–1706, doi:10.1021/acs.bioconjchem.6b00231.
36. Rossin, R.; Versteegen, R. M.; Wu, J.; Khasanov, A.; Wessels, H. J.; Steenbergen, E. J.; ten Hoeve, W.; Janssen, H. M.; van Onzen, A. H. A. M.; Hudson, P. J.; Robillard, M. S. Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. *Nat. Commun.* **2018**, *9*, 1484, doi:10.1038/s41467-018-03880-y.
37. Versteegen, R. M.; Wolter, T.; Rossin, R.; De Geus, M. A.; Janssen, H. M.; Robillard, M. S. Click-to-Release from trans-cyclooctenes: mechanistic insights and expansion of scope from established carbamate to remarkable ether cleavage. *Angew. Chemie - Int. Ed.* **2018**, *10.1002/an*, 1–11, doi:10.1002/anie.201800402.
38. Summer, D.; Grossrubatscher, L.; Petrik, M.; Michalcikova, T.; Novy, Z.; Rangger, C.; Klingler, M.; Haas, H.; Kaeopookum, P.; von Guggenberg, E.; Haubner, R.; Decristoforo, C. Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding. *Bioconjug. Chem.* **2017**, *28*, 1722–1733, doi:10.1021/acs.bioconjchem.7b00182.